Application of defibrotide in hepatic sinusoidal obstruction syndrome induced by hematopoietic stem cell transplantation

VernacularTitle:去纤苷在造血干细胞移植诱发的肝窦阻塞综合征中的应用
Author: Zhenli LIU ¹ ; Yu WANG ; Yali LIU ; Jing ZHANG
Author Information

1. 首都医科大学附属北京佑安医院　丙肝与中毒性肝病科，北京　100069
Keywords: Hepatic sinusoidal obstruction syndrome; Hematopoietic stem cell transplantation; Defibrotide
From: Chinese Journal of Hepatology 2021;29(1):92-96
CountryChina
Language:Chinese
Abstract: Hepatic sinusoidal obstruction syndrome (HSOS) is the most common early complication in patients with hematopoietic stem cell transplantation (HSCT). According to reports, the average incidence of HSOS post-HSCT is 13.7% (0~62%). HSOS may be accompanied by multiple organ failure, and the mortality rate can exceed 80% at 100 days of onset. Defibrotide is currently the safest and most effective drug used to prevent and treat HSOS post-HSCT. It is currently the only drug approved in the United States for the treatment of HSOS with lung/renal dysfunction post-HSCT. In addition, it has been approved in the European Union for the treatment of severe HSOS cases post-HSCT. This article briefly describes and summarizes the research progress, clinical application, pharmacokinetics, efficacy, safety, dose and treatment of defibrotide in HSOS post-HSCT.